Dr Stuart Faulkner
Programme and Operations Manager
Center for the Advancement of Sustainable Medical Innovation (CASMI)
Dr Stuart Faulkner has been the Programme and Operations Manager of CASMI, at Oxford University, since Nov 2015
Stuart has co-lead a variety of work streams in a recently completed large EU private-public partnership on adaptive pathways under the Innovative Medicines Initiative (IMI). It successfully explored and developed new conceptual frameworks to expedite patient access to transformative medicines at the European level. Further work continues in a new EU IMI project on enhancing sustainable patient engagement across the life cycle of medicine development, which commenced in early 2018.
In addition Stuart is responsible for co-leading a variety of consultancy and policy projects across a variety of stakeholders and areas. Stuart helps to further CASMI’s visibility, agenda, policy impact and its evolution, in its new location within primary care, through new collaborative projects and grant opportunities.
Stuart’s 16-year career in science has spanned a degree in Biosciences, a PhD in neuroscience, translational models of neonatal brain injury, early phase clinical trials and developing medical devices. A four-year move to Canada saw further research into stem cell treatments for cerebral palsy, coordinating a number of large observational studies in osteoarthritis, and helping to develop new models of healthcare. Stuart has extensive experience of multi-stakeholder projects, grant applications and publications.
In his spare time Stuart is active with many sports, travelling, culture, volunteering, and pursuing the love of the great outdoors.
Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?
Eichler HG. et al, (2018), Clinical pharmacology and therapeutics
Maximising value from a United Kingdom Biomedical Research Centre: study protocol
Greenhalgh T. et al, (2017), Health research policy and systems, 15
An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union
Meier A. et al, (2016), Clinical pharmacology and therapeutics, 100, 743 - 753
Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways
Faulkner SD. et al, (2016), Clinical pharmacology and therapeutics, 100, 730 - 742